Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 35, Issue -, Pages 30-39Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2017.05.002
Keywords
-
Categories
Funding
- European Research Council [338954]
- Italian Association of Cancer Research [12182, 14103]
- European Research Council (ERC) [338954] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Some enzymes degrading amino acids have evolved in mammals to dampen immune responses and maintain peripheral tolerance. The enzymes metabolizing L-arginine and L-tryptophan are particularly powerful, contributing to restrain immunity towards fetal tissues and establish neonatal tolerance. Solid tumors can hijack these formidable pathways to construct a microenvironment highly unfavorable to antitumor T lymphocytes able to recognize them, one of mechanisms for their immune evasion. In this review, we analyze emerging concepts in the cross-talk between cells expressing these enzymes, their immune regulatory functions and pharmacological approaches that can target them to enhance cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available